Medicure (OTCMKTS:MCUJF – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07), Zacks reports. Medicure had a negative return on equity of 54.55% and a negative net margin of 23.14%.
Medicure Stock Performance
Medicure stock traded up $0.04 during trading on Thursday, reaching $2.56. The company had a trading volume of 3,804 shares, compared to its average volume of 12,815. The company has a current ratio of 0.97, a quick ratio of 0.64 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $2.46 and its 200 day simple moving average is $1.27. The firm has a market capitalization of $26.83 million, a price-to-earnings ratio of -5.01 and a beta of 1.10. Medicure has a 52 week low of $0.67 and a 52 week high of $3.45.
Medicure Company Profile
Medicure Inc. is a Canadian pharmaceutical company focused on developing and commercializing products for cardiovascular disease. Through its U.S. operations, the company markets Aggrastat (tirofiban), an intravenous antiplatelet medicine used to help reduce the risk of certain cardiovascular events in patients with acute coronary syndrome, and Zypitamag (pitavastatin), a medicine for managing elevated cholesterol. The company serves customers in the United States and has historically focused its commercial activities on the U.S. cardiovascular market.
Further Reading
- Five stocks we like better than Medicure
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
